Skip to menu Skip to content Skip to footer
Dr Matthew Roberts
Dr

Matthew Roberts

Email: 
Phone: 
+61 7 334 66047

Overview

Background

Matthew J. Roberts, BSc, MBBS, PhD, FRACS (Urol)

  • Consultant Urologist, Royal Brisbane and Women’s (RBWH), Surgical Treatment and Rehabilitation Service (STARS), Queensland Health
  • Clinician Research Fellow, Metro North Hospital and Health Service
  • Group Leader & Associate Professor, The University of Queensland Centre for Clinical Research

Matthew is a medical graduate of The University of Queensland and completed Urology specialty training in Queensland and New South Wales. He completed his PhD under the supervision of Professor “Frank” Gardiner investigating new biomarkers for the early detection and characterization of prostate cancer.

Matthew is a surgeon-scientist, working clinically as a urologist and robotic surgeon at RBWH & STARS with academic appointment as Clinician Research Fellow at Metro North Health (Qld) and Associate Professor at UQCCR. His clinical and research interests are in Urologic cancers (e.g. prostate cancer), focusing on novel imaging and biomarkers, clinical trials, urological infections and innovation in urology. He has authored over 140 peer reviewed manuscripts in international journals and presented research at more than 20 international urology and clinical cancer meetings. He is a member of the EAU Prostate Cancer Guidelines Committee, Prostate Cancer Outcomes Registry (PCOR)-Queensland Steering Committee, Editorial Board of the BJU International, as well as Co-Convenor of the ANZUP 2024 ASM.

Availability

Dr Matthew Roberts is:
Available for supervision

Qualifications

  • Bachelor of Biomedical Science, The University of Queensland
  • Bachelor of Medicine, The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Urology

    All fields related to urology including urologic oncology, prostate cancer, kidney/renal cancer, bladder cancer and others. Urologic infections Quality-of-life and survivorship research Systematic review and meta-analysis.

Works

Search Professor Matthew Roberts’s works on UQ eSpace

249 works between 2000 and 2025

61 - 80 of 249 works

2023

Journal Article

Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review

Tariq, Arsalan, Stewart, Adam G., Desai, Devang J., Britton, Sumudu, Dunglison, Nigel, Esler, Rachel and Roberts, Matthew J. (2023). Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review. Current Urology, 17 (2), 100-108. doi: 10.1097/cu9.0000000000000159

Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review

2023

Conference Publication

Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)

Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins.

Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)

2023

Journal Article

Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?

Roberts, Matthew J., Hruby, George, Kneebone, Andrew, Martin, Jarad M., Williams, Scott G., Frydenberg, Mark, Murphy, Declan G., Namdarian, Ben, Yaxley, John W., Hofman, Michael S., Davis, Ian D. and Emmett, Louise (2023). Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?. BJU International, 132 (2), 146-148. doi: 10.1111/bju.16086

Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?

2023

Journal Article

Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer

Doan, Paul, Counter, William, Papa, Nathan, Sheehan‐Dare, Gemma, Ho, Bao, Lee, Jonathan, Liu, Victor, Thompson, James E., Agrawal, Shikha, Roberts, Matthew J., Buteau, James, Hofman, Michael S., Moon, Daniel, Lawrentschuk, Nathan, Murphy, Declan, Stricker, Phillip D. and Emmett, Louise (2023). Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer. BJU International, 131 (5), 588-595. doi: 10.1111/bju.15929

Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer

2023

Journal Article

Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work

Mehawed, Georges, Ranasinghe, Sachinka and Roberts, Matthew J. (2023). Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work. Urology Case Reports, 47 102356, 1-3. doi: 10.1016/j.eucr.2023.102356

Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work

2023

Conference Publication

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer

Buteau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, Lourenco, Richard De Abreu, Dhillon, Haryana M., Hofman, Michael S. and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. Genitourinary Cancers Symposium, Electr Network, 16-18 February 2023. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2023.41.6_suppl.TPS397

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer

2023

Conference Publication

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer

Buteau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, De Abreu Lourenço, Richard, Dhillon, Haryana M., Hofman, Michael S and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps397

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer

2023

Conference Publication

Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial

Kasivisvanathan, V., Murphy, D.G., Link, E., Lawrentschuk, N., O’Brien, J., Buteau, J.P., Roberts, M., Francis, R.J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J., Frydenberg, M., Shakher, R., Wong, L-M., Taubman, K., Lee, S.T., Hsiao, E., Nottage, M., Kirkwood, I., Iravani, A., Williams, S. and Hofman, M.S. (2023). Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial. EAU23 - 38th Annual EAU Congress, Milan, Italy, 10-13 March 2023. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(23)01275-7

Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial

2023

Journal Article

Extracellular vesicles for precision medicine in prostate cancer: is it ready for clinical translation?

Robinson, Harley, Roberts, Matthew J., Gardiner, Robert A. and Hill, Michelle M. (2023). Extracellular vesicles for precision medicine in prostate cancer: is it ready for clinical translation?. Seminars in Cancer Biology, 89, 18-29. doi: 10.1016/j.semcancer.2023.01.003

Extracellular vesicles for precision medicine in prostate cancer: is it ready for clinical translation?

2023

Journal Article

Variation in patient reported outcomes following radical prostatectomy: a bi-national registry-based study

O'Callaghan, Michael E., Roberts, Matthew J., Moretti, Kim L., Frydenberg, Mark, Gilbourd, Daniel, Mark, Stephen, Heathcote, Peter, Millar, Jeremy, PCOR-ANZ and Papa, Nathan (2023). Variation in patient reported outcomes following radical prostatectomy: a bi-national registry-based study. Urologic Oncology: Seminars and Original Investigations, 41 (2), 105.e9-105.e18. doi: 10.1016/j.urolonc.2022.10.020

Variation in patient reported outcomes following radical prostatectomy: a bi-national registry-based study

2023

Journal Article

Plain x‐ray misses many ureteric calculi: Time to challenge the old dogma?

McGeorge, Stephen, Loh, Brendon, Shibu, Ryan, Dobeli, Karen, Brown, Nathan J., Esler, Rachel, Hacking, Craig, Purvey, Megan and Roberts, Matthew J. (2023). Plain x‐ray misses many ureteric calculi: Time to challenge the old dogma?. BJUI Compass, 4 (1), 59-61. doi: 10.1002/bco2.192

Plain x‐ray misses many ureteric calculi: Time to challenge the old dogma?

2022

Journal Article

Using PSMA imaging for prognostication in localized and advanced prostate cancer

Roberts, Matthew J., Maurer, Tobias, Perera, Marlon, Eiber, Matthias, Hope, Thomas A., Ost, Piet, Siva, Shankar, Hofman, Michael S., Murphy, Declan G., Emmett, Louise and Fendler, Wolfgang P. (2022). Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nature Reviews Urology, 20 (1), 23-47. doi: 10.1038/s41585-022-00670-6

Using PSMA imaging for prognostication in localized and advanced prostate cancer

2022

Journal Article

68Ga‐PSMA PET / CT false positive liver metastasis prior to radical prostatectomy

Saad, Jeremy, Shanmugasundaram, Ramesh, Wong, Veronica, Le, Ken, Arianayagam, Mohan and Roberts, Matthew J. (2022). 68Ga‐PSMA PET / CT false positive liver metastasis prior to radical prostatectomy. ANZ Journal of Surgery, 93 (4), 1029-1030. doi: 10.1111/ans.18051

68Ga‐PSMA PET / CT false positive liver metastasis prior to radical prostatectomy

2022

Conference Publication

Genetic testing in prostate cancer: a scoping literature review

Edmunds, Kim, Arora, Shiksha, Roberts, Matthew, Fairbairn, David, Scuffham, Paul, Smith, David, Chambers, Suzanne, Horvath, Lisa and Tuffaha, Haitham (2022). Genetic testing in prostate cancer: a scoping literature review. COSA's 49th Annual Scientific Meeting Equitable cancer care for all: Gender, identity, culture, geography, and disease should not matter, Online, 2–4 November 2022. Chichester, West Sussex United Kingdom: Wiley-Blackwell.

Genetic testing in prostate cancer: a scoping literature review

2022

Journal Article

The PRIMARY score: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis

Emmett, Louise M., Papa, Nathan, Buteau, James, Ho, Bao, Liu, Victor, Roberts, Matthew, Thompson, James, Moon, Daniel, Sheehan-Dare, Gemma, Alghazo, Omar, Agrawal, Shikha, Murphy, Declan G., Stricker, Phillip, Hope, Thomas A. and Hofman, Michael (2022). The PRIMARY score: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. Journal of Nuclear Medicine, 63 (11), 1644-1650. doi: 10.2967/jnumed.121.263448

The PRIMARY score: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis

2022

Journal Article

Cellular milieu in clear cell renal cell carcinoma

Raghubar, Arti M., Roberts, Matthew J., Wood, Simon, Healy, Helen G., Kassianos, Andrew J. and Mallett, Andrew J. (2022). Cellular milieu in clear cell renal cell carcinoma. Frontiers in Oncology, 12 943583, 1-10. doi: 10.3389/fonc.2022.943583

Cellular milieu in clear cell renal cell carcinoma

2022

Journal Article

Testicular torsion: not just in young men

Saad, Jeremy, Shanmugasundaram, Ramesh, Heywood, Sean, Varol, Celi and Roberts, Matthew J. (2022). Testicular torsion: not just in young men. Journal of Urological Surgery, 9 (3), 215-217. doi: 10.4274/jus.galenos.2021.2021.0085

Testicular torsion: not just in young men

2022

Journal Article

Low‐Grade Prostate Cancer Should Still be Labeled Cancer

Iczkowski, Kenneth A., Molina, Mariel, Egevad, Lars, Bostwick, David G., van Leenders, Geert J.L.H., La Rosa, Francisco G., van der Kwast, Theodorus, Berney, Daniel M., Evans, Andrew J., Wheeler, Thomas M., Leite, Katia R.M., Samaratunga, Hemamali, Srigley, John, Varma, Murali, Tsuzuki, Toyonori, Lucia, M. Scott, Crawford, E. David, Harris, Richard G., Stricker, Philip, Lawrentschuk, Nathan, Woo, Henry H., Fleshner, Neil E., Shore, Neal D., Yaxley, John, Bratt, Ola, Wiklund, Peter, Roberts, Matthew, Cheng, Liang and Delahunt, Brett (2022). Low‐Grade Prostate Cancer Should Still be Labeled Cancer. BJU International, 130 (6), 741-743. doi: 10.1111/bju.15886

Low‐Grade Prostate Cancer Should Still be Labeled Cancer

2022

Journal Article

Mineral content variations between Australian tap and bottled water in the context of urolithiasis

Kwok, Michael, McGeorge, Stephen, Roberts, Matthew, Somani, Bhaskar and Rukin, Nicholas (2022). Mineral content variations between Australian tap and bottled water in the context of urolithiasis. BJUI Compass, 3 (5), 377-382. doi: 10.1002/bco2.168

Mineral content variations between Australian tap and bottled water in the context of urolithiasis

2022

Journal Article

Event‐free survival after radical prostatectomy according to PSMA PET and EAU Biochemical Recurrence Risk Groups

Roberts, Matthew J., Chatfield, Mark D., Hruby, George, Nandurkar, Rohan, Roach, Paul, Watts, Jo Anne, Cusick, Thomas, Kneebone, Andrew, Eade, Thomas, Ho, Bao, Nguyen, Andrew, Tang, Colin, McCarthy, Michael, Francis, Roslyn, Stricker, Phillip and Emmett, Louise (2022). Event‐free survival after radical prostatectomy according to PSMA PET and EAU Biochemical Recurrence Risk Groups. BJU International, 130 (S3), 32-39. doi: 10.1111/bju.15762

Event‐free survival after radical prostatectomy according to PSMA PET and EAU Biochemical Recurrence Risk Groups

Funding

Current funding

  • 2024 - 2030
    Prostate Cancer - FDG - Spatial Imaging (Spatial biology meets PET imaging: A non-invasive, Google Map for Prostate cancer)
    PA Research Foundation
    Open grant

Past funding

  • 2022 - 2025
    Randomized, Double-Blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety and Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Path
    Janssen-Cilag Pty Limited (Janssen-Cilag Australia)
    Open grant
  • 2022 - 2023
    Prospective surgeon-led trials in Prostate Cancer for personalised management and healthcare sustainability
    Viertl Clinical Investigator Award
    Open grant
  • 2021 - 2022
    De-Intensification of Post ProstatEctomy Radiotherapy (DIPPER) incorporating clinical and imaging-based risk stratification: Part 1 - Pilot study (additional site)
    ANZUP Below the Belt Research Fund
    Open grant
  • 2021
    A prospective clinical evaluation of prostate biopsy under local anaesthetic to optimise health care resources: feasibility study
    Metro North Hospital and Health Service
    Open grant
  • 2021
    Staging of aggressive prostate cancer 'invisible' to PSMA-PET: The FDG-PET for INvisible Disease (FIND) Trial
    Metro North Hospital and Health Service
    Open grant
  • 2018
    Combined TMPRSS2:ERG, PCA3 and SChLAP1 RNA in Urine for selective detection of Aggressive Prostate Cancer
    Metro North Hospital and Health Service
    Open grant
  • 2015
    Exploring new Paradigms in Pre-prostate cancer detection and management
    Royal Brisbane and Women's Hospital Foundation
    Open grant
  • 2014 - 2016
    Exploring new Paradigms in Pre-prostate cancer detection and management
    Royal Brisbane and Women's Hospital Foundation
    Open grant
  • 2013
    Optimising collection for metabonomic profiling of ejaculate to complement PCR in prostate cancer detection
    Royal Brisbane and Women's Hospital
    Open grant

Supervision

Availability

Dr Matthew Roberts is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Roles of image fusion and 3D technology in urology: exploration and clinical integration for personalised devices

    Associate Advisor

    Other advisors: Professor Kristofer Thurecht, Dr Nick Rukin

Media

Enquiries

For media enquiries about Dr Matthew Roberts's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au